Balaji Amines Limited (BALAMINES) announced its unaudited financial results for the quarter and half year ended September 30th, 2026. The consolidated revenue for Q2 FY27 stood at ₹472 crore, up from ₹348 crore in Q2 FY26. The EBITDA was ₹106 crore compared to ₹67 crore in the same quarter last year. Net profit for the quarter was ₹67 crore, significantly higher than the ₹37 crore reported in Q2 FY26.

Financial Performance

The company’s total revenue for Q2 FY27 was ₹472 crore, a notable increase from ₹348 crore in Q2 FY26. The EBITDA margin stood at 22%, down from 26% in Q1 FY27 but up from 19% in Q2 FY26. The profit after tax (PAT) for the quarter was ₹67 crore, up from ₹37 crore in the previous year’s quarter. Diluted earnings per share (EPS) for Q2 FY27 stood at ₹20.76 per equity share, compared to ₹10.67 in Q2 FY26.

Growth Drivers

The company continues to strengthen its growth platform through capacity expansion and a focus on value-added specialty chemicals. Commercial production has commenced at the expanded Acetonitrile (ACN) facility, increasing installed capacity to 1,440 TPM. The upgraded plant incorporates advanced technology and enhanced process efficiencies, positioning the company to improve operational performance over the medium term.

The successful commissioning of the 100,000 TPA Dimethyl Ether (DME) plant, India’s first commercial-scale DME facility, has established the company in a high-potential import substitution market with applications spanning healthcare, personal care products, and fuel applications. The next phase of work is in the pipeline to establish a robust network of customers as the company has already studied the ever-expanding Aerosol market. Opportunities for export of DME are explored regularly.

The next product planned for commercialization is N-Methyl Morpholine (NMM), further expanding the specialty chemicals portfolio. In parallel, Balaji Speciality Chemicals is progressing with its expansion program that is aimed at increasing the share of high-value specialty chemicals. The Unit-I brownfield expansion, comprising EDA derivatives such as DETA, TETA, Piperazine, AEEA, and AEP, remains on track for commissioning during the end of FY27. The Unit-II greenfield project at MIDC, Chincholi, which will manufacture HCN, NaCN, EDTA, and EDTA-2Na, is targeted for commissioning in Q4 FY27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, ‘Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. As we enter H2 FY27, our focus is firmly on driving higher utilization, improving operating efficiencies and translating recent investments into stronger earnings growth. The commissioning of the upgraded Acetonitrile (ACN) facility and the DME plant marks an important step in expanding our presence in value-added and import-substitution products. We are now focused on scaling these capacities and unlocking their full commercial potential. We have also improved the process of Di Isopropylamine (DIPA) as continuous efforts yielded this success. Overall, the volumes have dented due to various external factors, however, the company has leveraged its strength in stabilising the product portfolio to keep the top line stable and continuing the efforts to strengthen the bottom line. Our growth pipeline remains robust, with N-Methyl Morpholine (NMM) and multiple specialty chemical projects progressing as planned. These investments will further strengthen our specialty chemicals portfolio, enhance integration and expand our participation in high-growth end markets. With a stronger product mix, a visible expansion roadmap and a disciplined focus on execution, we remain confident in our ability to drive sustainable growth, improve earnings quality and create long-term value for shareholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Balaji Amines Limited

Balaji Amines Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Balaji falls 9.7% over three months and has not found a floor yet. Revenue contracts at -15.6% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 66% of its 52-week range with RSI at 45. In other words, neither side has a clear edge right now. The stock holds up despite -15.6% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Balaji Amines Limited.

Indogulf Cropsciences Limited (NSE: IGCL | BSE: 544432) announced its consolidated unaudited financial results for the quarter and half year ended September 30, 2026, showcasing robust performance. The company’s EBITDA rose 27% year-on-year to ₹41 crore, while PAT increased by 24% to ₹26 crore. The EBITDA margin expanded by 300 basis points to 16%, reflecting disciplined cost management and a favorable product mix.

Financial Performance Snapshot

The company’s total income for Q2 FY27 stood at ₹256 crore, up 3% year-on-year. Despite weak monsoon conditions, the sequential revenue growth was 52% QoQ, indicating improved business momentum. The PAT margin improved to 10% from 8% due to lower finance costs and enhanced operating efficiencies.

Half-Year Performance

For H1 FY27, revenue from operations was ₹424 crore, showing a marginal decline of 3% YoY. However, gross profit increased by 7% to ₹123 crore, with the gross margin improving to 29%. EBITDA grew 20% to ₹50 crore, and the EBITDA margin expanded to 12%. The PAT increased 14% to ₹28 crore, with the PAT margin improving to 7%.

Looking Ahead

Commenting on the performance, Mr. Sanjay Aggarwal, Managing Director, Indogulf Cropsciences Limited, said: “We are pleased with our strong performance in Q2 FY27. The first half has seen similar progress, and we are entering the second half with strong business momentum. The national focus on raising farm productivity and farmer incomes, growing adoption of modern crop protection and crop nutrition, and the accelerating shift towards sustainable and biological solutions are creating strong tailwinds for integrated players like Indogulf.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indogulf Cropsciences Limited

Indogulf Cropsciences Limited belongs to the Basic Materials › Agricultural Inputs sector. Here’s a quick read on where the business and the stock stand today.

Indogulf falls 13.7% over three months and has not found a floor yet. The PEG of 0.55 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 5.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock sits at 19% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.6% and profits at 21.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 13.7% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Indogulf Cropsciences Limited.

National Aluminium Company Limited (NALCO) (NATIONALUM) has delivered its best-ever financial performance for the first half of FY 2026–27 since its inception, achieving record levels across all key financial parameters. The company’s total income for H1 FY 2026–27 stood at Rs.11,143 crore, registering a robust growth of 33% compared to Rs.8,374 crore in the corresponding period of the previous year. Demonstrating strong operational and financial performance, EBITDA increased by 50% to Rs.5,539 crore, while PBT and PAT recorded impressive growth of 55% and 54%, reaching Rs.5,160 crore and Rs.3,837 crore, respectively compared to the corresponding period of FY 2025–26.

Key Highlights

NALCO has achieved its highest-ever aluminium cast metal production of 2.35 lakh tonnes for the first half of FY 2026–27. Additionally, the company has recorded its highest-ever cumulative domestic sale of alumina and metal sales in H1 FY 2026–27. The company has announced an interim dividend of Rs.4.50 per equity share (90% on the face value of Rs.5 each), amounting to Rs.826.48 crore for FY 2026–27.

Looking Ahead

Shri Brijendra Pratap Singh, CMD, NALCO, said that the company’s strong performance during Q2 and H1 of FY 2026-27 was driven by robust operational efficiency, strong physical performance, and favourable market conditions supported by prudent marketing strategies. NALCO remains committed to its expansion initiatives, with the 5th stream expansion of the alumina refinery at the advanced stage of commissioning and groundwork for the proposed 0.5 MTPA brownfield smelter expansion project at Anugola, Odisha, progressing steadily.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of National Aluminium Company Limited

National Aluminium Company Limited belongs to the Basic Materials › Aluminum sector. Here’s a quick read on where the business and the stock stand today.

National moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 0.15 is extremely low. Either the market misses the growth story, or there is a catch worth investigating. Industry-leading margins of 34.9% reflect exceptional pricing power and operational efficiency. The stock holds at 46% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 7.8% and profits at 59.3%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of National Aluminium Company Limited.